Heron Therapeutics Inc (NASDAQ:HRTX) price closed lower on Friday, April 12, dropping -1.02% below its previous close.
A look at the daily price movement shows that the last close reads $2.94. The company’s 5Y monthly beta was ticking 1.71. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.22 and 52-week low of $0.50. The stock subtracted -3.32% on its value in the past month.
Heron Therapeutics Inc, which has a market valuation of $437.46 million, is expected to release its quarterly earnings report May 09, 2024 – May 13, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give HRTX a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.
The overview shows that HRTX’s price is at present 2.72% off the SMA20 and 8.76% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 57.49, with weekly volatility standing at 6.35%. The indicator jumps to 6.66% when calculated based on the past 30 days. Heron Therapeutics Inc (NASDAQ:HRTX)’s beta value is holding at 1.70, while the average true range (ATR) indicator is currently reading 0.20. An analysis of the Heron Therapeutics Inc (NASDAQ:HRTX) stock in terms of its daily trading volume indicates that the 3-month average is 2.64 million.
Current records show that the company has 150.29M in outstanding shares. The insiders’ percentage holdings are 5.10% of outstanding shares while the percentage share held by institutions stands at 71.14%. But the 71.18% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
